



ORIGINAL CONTRIBUTIONS

Functional Outcome After Common Poststroke Complications Occurring in the First 90 Days

Gitta Rohweder, MD, Hanne Ellekjær, MD, PhD, Øyvind Salvesen, PhD, Eirik Naalsund, RN, and Bent Indredavik, MD, PhD

The aim of this study was to explore the associations of common medical complications with functional outcome at 90 days post stroke.

Patients with unselected acute stroke were included and observed for 16 predefined complications during the first week. Fifty percent (244 patients) were allocated to follow-up of 13 complications until 90 days and then assessed with the modified Rankin Scale 90. Common complications were defined as complications with frequencies of $\geq 5\%$. Ordinal logistic regression (worsened outcome), as well as binary logistic regression for severe dependency and death (modified Rankin Scale score > 3) was performed.

Seven of the 13 complications occurred at a frequency $\geq 5\%$. Recurrent stroke and chest infection were found to have an odds ratio for worsened outcome of 7.45 (95% confidence interval, 2.83–20.96; $P < 0.0001$) and 3.28 (95% confidence interval, 1.16–9.29; $P = 0.025$), respectively. Infections other than chest infections and urinary tract infections had an odds ratio for worsened outcome of 1.59 (95% confidence interval, 1.12–2.24; $P = 0.009$) and falls an odds ratio of 1.43 (95% confidence interval, 1.06 to 1.93; $P = 0.021$). Myocardial infarction, urinary tract infections, and pain were not associated with a worsened outcome in terms of modified Rankin Scale 90.

Recurrent stroke and chest infections were strongly associated with a worsened outcome. Other infections and falls were associated with less worsening. For myocardial infarction, urinary tract infections, and pain no association with functional outcome was found. Active strategies for prevention and early treatment of the first 2 complications seem advisable; patient monitoring as part of comprehensive stroke unit care should ensure timely identification and treatment of all complications.

Key Words: complications ■ patient outcome assessment ■ stroke ■ stroke unit

© 2014 American Heart Association, Inc.

Stroke is a serious global public health problem with an annual incidence varying from 100 to 400 cases in 100 000 inhabitants, and a leading cause of death and disability, both in high- and low-income countries.¹ The crude annual incidence of stroke in Central Norway is known to be 300 in 100 000 inhabitants.² The reported 1-month case-fatality rate from different

countries varies between 14% and 34%.¹ Although the majority of deaths are accounted for by neurological sequelae of the stroke, a significant proportion has been judged to be caused by immobility and cardiac disease.³ Stroke unit (SU) care reduces the case-fatality by 18%, and it has been suggested that the prevention and timely treatment of medical complications may account for most of the survival benefits related to SUs.^{4,5}

Poststroke complications have been studied both in the acute phase and in the rehabilitation phase.^{6–8} They can be categorized into 3 groups: (1) neurological complications (cerebral edema, stroke progression, stroke recurrence, seizures, anxiety, and depression), (2) cardiovascular complications, and (3) complications of immobility (chest infection, urinary tract infection [UTI], other infections, dehydration, venous thromboembolism, falls, pressure sores, and pain).^{3,5} The percentage of patients experiencing ≥ 1 complication within the first month post stroke is reported with great variation at 24%,⁹ 59%,⁶ 85%,⁸ and 95%.⁷ In our comprehensive SU, the frequencies of common complications were 64% within the first week and 82% during the first 3 months.¹⁰ Studies relating stroke complications to parameters of functional outcome are scarce, yet suggest that the majority of complications are associated with a reduction in functional outcome.^{7,9}

The aim of the present study was to examine the association between complications and functional outcome at 90 days for patients treated in an SU, followed by an early supported discharge service, which both have been evaluated in randomized trials and have shown beneficial effects on functional outcome.^{11,12}

SUBJECTS AND METHODS

The SU, Department of Medicine at the University Hospital of Trondheim, serves as the primary hospital for $\approx 200\,000$ inhabitants of South Trondelag and as the tertiary hospital for Central Norway. All patients, admitted consecutively between January 1, 2002, and May 15, 2003, and presenting with symptoms consistent with acute stroke ($n=664$), were included in the study if the following criteria were fulfilled: (1) a diagnosis of acute stroke according to the World Health Organization's definition, (2) computerized tomographic scan exclusion of alternative pathologies (eg, tumor, trauma, infection, and vasculitis; $n=110$), and (3) admission to the SU within 24 hours of stroke onset ($n=54$). Screening for inclusion was halted after completed inclusion of 500 patients. Of the 500 patients thus eligible for inclusion, 11 did not wish to participate during follow-up. A total of 489 patients were included in the analysis of complications during the first week.¹⁰

Fifty percent of these patients were randomly allocated to 90-day follow-up, and these 244 patients are the contributors to this study (Figure 1).




Figure 1. Patient flow.

All patients received initial diagnostic evaluation and treatment in accordance with our SU protocol.^{13,14} It stresses physiological homeostasis, a strategy for early mobilization and integration of medical and nursing care, and rehabilitation via a multidisciplinary team. There was a strong focus on prevention of complications, including routine swallowing evaluation before any oral-intake, frequent ultrasound assessment for urinary retention and the use of intermittent urinary catheterization as necessary.

After discharge from the SU, the patients were followed up by an early supported discharge service, previously described.¹¹ As part of this service, all patients received an outpatient follow-up medical evaluation 4 weeks after discharge. At 90 days, a home-visit and functional assessment using modified Rankin Scale (mRS) scores¹⁵ were performed by a staff-member unfamiliar with the patient.

Assessment of Complications

During the first week after admission, patients were screened daily for 16 prespecified complications by specially trained physicians, nurses, and physical therapists.¹⁰ Two-hundred forty four patients were allocated to weekly follow-up via telephone to the patient or the primary caregiver for 3 months and with assessment of the following complications: stroke recurrence, seizure, chest infection, UTI, other infections, falls (serious and nonserious), pressure sores, pulmonary embolism, deep vein thrombosis, myocardial infarction, and pain (shoulder and other). All complications were based on a clinical diagnosis, and their definitions were similar to the

definitions used in previous studies.^{6,8} The definitions and the frequencies of these complications have been published previously.¹⁰

Data Analysis

Complications occurring in 5% of patients or more over the entire 3-month period were defined as common complications and were analyzed for their association with functional outcome at 90 days. Ordinal logistic regression was performed to calculate an odds ratio (OR) for worsened outcome and binary logistic regression with a cutoff between mRS 3 and 4 was performed to calculate an OR for bad outcome. Both were adjusted for the potential confounders: age, sex, prestroke mRS and Scandinavian stroke scale (SSS) day 1; the latter represents stroke severity. Ordinal logistic regression analysis is judged to provide a more sensitive estimate than analysis of a dichotomized-outcome and it was, therefore, chosen as a primary end point.^{16,17} A cutoff between mRS 3 and 4 was used, when the conditions of the parallel line-test for proportionality were not met. The calculations were performed in SPSS and Stata.

Ethics

This study was part of a larger investigation on recovery after stroke and was approved by the regional ethics committee.

RESULTS

The patients baseline characteristics are shown in [Table 1](#). A total of 56% of patients were women and the mean age was 76.5 years (SD±9.8). Ninety percent had an ischemic stroke and 10% had a hemorrhagic stroke. Mean SSS day 1 was 40.3 (SD±16.6). Mean estimated prestroke mRS was 1.6 (SD±1.1) and mean mRS day 1 was 3.47 (SD±1.3).

Table 1. Baseline Characteristics of the Patients (n=244) ([Table view](#))

Characteristics	n	%
Women	137	56
Age, y, mean±SD	76.5±9.8	
Risk factors		
Hypertension	93	38
Previous stroke	47	19
Atrial fibrillation	46	19
Diabetes mellitus	30	12
Previous myocardial infarction	35	14
Smoking	48	20
TIA	24	10
Diagnosis		
Ischemic stroke	219	90
Hemorrhagic stroke	25	10

TIA indicates transient ischemic attack.

As presented in [Table 2](#), the following 7 complications occurred in ≥5% of patients: recurrent stroke 5%, myocardial infarction (MI) 7%, chest infection 17%, UTI 28%, other infections 13%, falls (combined-serious and nonserious falls) 29%, and pain (combined-shoulder and diffuse pain)

57%. The following complications seizures, pressure sores, pulmonary embolism, and deep vein thrombosis occurred at a frequency of 2.5, 2.9, 1.2, and 2.5%, respectively and were not analyzed further. mRS at day 90 (mRS90) varied greatly between the complications. In unadjusted analysis, recurrent stroke, MI, and chest infection were associated with a worsening of survival and function (mRS \geq 3) at 90 days; pain and falls were to a lesser degree (Figure 2).

Table 2. Frequency of Complications and Distribution of Outcomes in Terms of mRS90 (Table view)

Complication	n	% of Cohort	Age, y	Earlier mRS, Mean \pm SD	mRS90, Mean \pm SD	mRS90, 0–3, %	mRS90, 4–6, %	mRS90, 6, %
Whole cohort	244	100	77 \pm 9	1.6 \pm 1.1	3.0 \pm 1.8	66	34	17
Recurrent stroke	12	5	78 \pm 6	1.6 \pm 1.2	4.7 \pm 1.6	25	75	42
MI	17	7	84 \pm 6	2.1 \pm 1.4	4.8 \pm 1.6	23	77	53
Chest infection	42	17	82 \pm 7	2.0 \pm 1.2	4.7 \pm 1.6	19	81	45
UTI	68	28	81 \pm 9	2.0 \pm 1.1	3.9 \pm 1.5	40	60	19
Other infection	31	13	78 \pm 9	1.4 \pm 0.9	3.4 \pm 1.6	48	52	13
Falls	70	29	76 \pm 10	1.4 \pm 0.9	3.1 \pm 1.2	69	31	4
Pain	140	57	77 \pm 10	1.5 \pm 1.1	3.9 \pm 1.6	66	34	12

Descriptive data. MI indicates myocardial infarction; mRS, modified Rankin Scale; and UTI, urinary tract infection.




Figure 2. Distribution of modified Rankin Scale (mRS) scores at 90 days.

Table 3 shows the results of the outcome analysis adjusted for age, sex, prestroke mRS and SSS day 1. According to both the shift and the dichotomized analyses recurrent stroke and chest infection had an OR for worsened outcome of 7.45 (95% confidence interval [CI], 2.83–20.96; $P<0.0001$) and 3.28 (95% CI, 1.16–9.29; $P=0.025$), respectively, and an OR for bad outcome (mRS $>$ 3) of 10.45 (95% CI, 1.03–38.93; $P<0.0001$) and 2.52 (95% CI, 1.14–8.53; $P=0.022$). Infections other than chest and UTI, as well as falls, had ORs for worsened outcome of 1.59 (95% CI, 1.12–2.24; $P=0.009$) and 1.43 (95% CI, 1.06–1.93; $P=0.021$), respectively. The ORs for bad outcome (mRS $>$ 3) were 2.09 (95% CI, 1.15–3.80; $P=0.015$) and 1.41 (95% CI, 1.06–1.88;

$P=0.019$). Myocardial infarction, as well as UTI and pain, was not associated with a reduction in functional outcome.

Table 3. OR for Worsened Outcome (Ordinal Logistic Regression) and Bad Outcome (mRS>3 at Day 90) (Table view)

Complication	OR (95% CI) for Worsened Outcome	<i>P</i> Value	OR (95% CI) for mRS>3	<i>P</i> Value
Recurrent stroke	7.45 (2.83–20.96)	<0.0001	10.45 (1.03–38.93)	<0.0001
MI	1.83 (0.62–5.36)	0.272	1.89 (0.42–8.53)	0.408
Chest infection	3.28 (1.16–9.29)	0.025	2.52 (1.14–5.54)	0.022
UTI	1.19 (0.63–1.74)	0.323	1.33 (0.91–1.93)	0.137
Other infection	1.59 (1.12–2.24)	0.009	2.09 (1.15–3.80)	0.015
Falls	1.43 (1.06–1.93)	0.021	1.41 (1.06–1.88)	0.019
Pain	1.00 (0.92–1.09)	0.961	0.94 (0.80–1.10)	0.439

Ordinal logistic regression was performed, correcting for age, sex, prestroke mRS, and SSS day 1 (worsened outcome). Binary logistic regression for severe dependency or death (mRS>3) was performed correcting for the same confounders (bad outcome). CI indicates confidence interval; MI, myocardial infarction; mRS, modified Rankin Scale; OR, odds ratio; SSS, Scandinavian stroke scale; and UTI, urinary tract infection.

DISCUSSION

Functional outcome after a stroke is in large part determined by the nature of the incident stroke. Other established factors associated with reduced functional outcome are advanced age and a reduced level of premorbid function.^{18,19} In this study, we were able to show that recurrent stroke and chest infection were strongly associated with reduced functional outcome at 90 days. Falls and other infections had a much weaker association with reduced functional outcome. No other complication assessed was associated with a reduction in function.

Five percent of our patients were found to have a recurrent stroke. Other studies reported a frequency of 2% to 18%.^{7–9} In our study, this complication had an OR of 7.5 for a worsened outcome and an OR of 10.5 for major disability or death. Early work-up for transient ischemic attack or minor stroke reduced the 90-day recurrent stroke rate from 10.3% to 2.1% in the Oxford Vascular Study.²⁰ Analogously, recurrent stroke can be considered a likely failure of prevention, justifying a repeated work-up with an aim to improve prophylaxis. Large artery disease, previous MI, and atrial fibrillation seem to be the factors predisposing toward early recurrence and should be actively sought after.^{21–23}

A total of 17% of our patients had a chest infection, with an adjusted OR of 3.3 and 2.5 for worsened outcome and for dependency and death, respectively. This complication is reported at a frequency of 10% to 22% in other studies and known to be associated with high-mortality.^{6–9} In a study of 14 293 US Medicare patients admitted for stroke, pneumonia was identified in 6.9% of patients and conferred a 3-fold increase in 30-day mortality.²⁴ The stroke-related causes are judged to be multifactorial: reduced swallowing ability, reduced mobility and thereby lung-mechanics, and central nervous system injury-induced immune depression.^{25–27} Performing a swallowing evaluation before any oral-intake has been shown to decrease the incidence of aspiration pneumonia 3-fold.²⁸ Preventive use of antibiotics is under investigation as a possible strategy in high-risk patients.²⁹ Early initiation of antibiotic therapy is generally recommended and seems to be one of the interventions that make SU care so effective.⁵ Greater emphasis on patient-mobilization is likely another important preventive aspect of SU care. Although it is

established that mobilization within 7 days reduces the number of serious complications, and too much time spent in bed is detrimental, the optimal timing (within 24, 48, or 72 hours from onset of a stroke) and quantity of mobilization are not clear yet.^{30–32} Incentive spirometry, commonly used in the postoperative management of patients, could be an accessory measure in those patients, which cannot be mobilized to a standing position. Its use seems most promising in the context of a multifactorial care program, including oral care and mobilization, which has been shown to reduce postoperative pneumonia by 38%.³³

Infections other than chest infection and UTI occurred in 13% of patients and represent various causes, mostly skin and intravenous line infections, and also sepsis and cholecystitis. This group of infections was shown to be associated with worsened outcome with an OR of 1.59, and severe disability and death with an OR of 2.09. Scant reports describe a frequency between 7% and 10%.^{34,35} No association with a reduction in functional outcome was found in a similar analysis.³⁴ The variability in the findings likely reflects the variability in the case-mix. Measures to counteract nosocomial infections and routine SU care constitute preventive efforts.

Falls occurred in 29% of the cohort. This frequency compares with a range of 2.2% to 26% reported.^{6,8,9} A minority (3%) of patients sustained a concomitant serious soft tissue injury or fracture. Falls (all combined) conferred an OR of 1.43 for worsened outcome and an OR of 1.41 for disability or death. This association, although statistically significant, was of a lesser magnitude than the association observed between a recurrent stroke or chest infection and reduction in functional outcome. Appropriate interventions to reduce falls should increase the patient's coping ability and concomitantly reduce his/her fear of falling to counteract the downward spiral of fear, less physical activity, decline in physical ability and further increase in the risk of falling.^{36,37}

A poststroke MI occurred in 7% of the patients. The literature reported a frequency of MI or cardiac failure of 2% to 4% in patients poststroke.^{6,7,9} In our study, despite being associated with a high-rate of disability and mortality in the unadjusted analysis, this serious event, which occurred mainly in older patients, was not independently associated with a reduction in functional outcome.

UTI occurred in 28% of patients. The reported frequency varies between 7% and 27%.^{6–9,34,38} This infection was not independently associated with a reduction in 90-day function in our study. A similar result was obtained in a study of 412 patients by Stott et al.³⁴ Pain, including shoulder-pain and diffuse pain, occurred in 57% of patients. No association with functional outcome at 90 days could be found.

The reported frequency varies widely for most of the complications, and our results are usually at the higher end of this range. Variations in definition of complications, timing and duration of follow-up, and case-mix are probably contributing factors to the variation in complication rates. Although our results could in part imply a failure of prevention, they might, alternatively, reflect thorough screening procedures. We do think that a foremost strength of our study is the fact that it was performed in an SU combined with an organized follow-up service (early supported discharge), which has shown good outcomes previously for patients with stroke, and whose members were actively searching for complications. With this approach, one would expect to best approximate a complete reporting of events. Another strength of the study is the choice of end point, because the functional outcome at 3 months is a predictor for long-term survival.³⁹

A potential weakness of our study is the lack of assessment for neuropsychiatric complications: delirium, depression and poststroke fatigue. These could be assessed concomitantly with the assessment of softer end points and patient reported outcomes.

Ten years have passed between the conduction of the study and this analysis. During this time, stroke care may have improved, and this may have lead to a reduction in the frequency of

complications. However, the relative associations with outcome should not have been affected by this process. To our knowledge, an equally comprehensive outcome analysis with regards to complications has not become available in the literature in the intervening years.

Looking to the future, it would be interesting to explore, which of these complications are associated with an increase in morbidity and mortality in the longer term. Especially important is a follow-up in regards to falls, which according to the geriatric literature conveys a serious prognosis and is important in patient safety campaigns.⁴⁰ Preventive antibiotics for aspiration pneumonia in high-risk patients and a multifactorial approach to mobilization and chest physical therapy in the context of an SU deserve further study.

CONCLUSIONS

In our study, 2 complications, recurrent stroke and chest infections, were strongly associated with a worsening of outcome at 90 days post stroke. Other infections and falls were associated with worsening of a lesser magnitude. Pain, although common, seemed not to be associated with a reduction of functional outcome. Cardiovascular assessment and secondary stroke prevention, as well as the prevention and treatment of aspiration pneumonia, seem important in stroke care. Patient monitoring as part of comprehensive SU care should ensure timely identification and treatment of all complications and is applicable in all healthcare settings.⁴¹

ARTICLE INFORMATION

Received July 7, 2014; revision received September 30, 2014; accepted October 17, 2014; published online November 13, 2014.

The online-only Data Supplement is available with this article at <http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.114.006667/-/DC1>.

Correspondence

Correspondence to Gitta Rohweder, MD, Department of Medicine, Stroke Unit, Nevrosenter vest, St Olav's Hospital, Harald Hardraades gate 5, 7030 Trondheim, Norway. E-mail gitta.rohweder@ntnu.no

Affiliations

From the Stroke Unit, Department of Internal Medicine, St Olav's Hospital, University Hospital of Trondheim, Trondheim, Norway (G.R., H.E., E.N., B.I.); and Department of Neuroscience (G.R., B.I.) and Unit for Applied Clinical Research (Ø.S.), Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

Acknowledgments

We are grateful to the members of our stroke unit staff for their contributions to this study and to Ingrid Riphagen from the Unit for Applied Clinical Research, Faculty of Medicine at Norwegian University of Science And Technology, for her help in editing the article.

Sources of Funding

This study was supported by grants from the Regional Health Service in Central Norway, the Norwegian University of Science and Technology in Trondheim, and the Stroke Unit Research Fund.

Disclosures

None.

REFERENCES

1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol.* 2009;8:355–369. [Crossref](#). [PubMed](#).
2. Ellekjaer H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. *Stroke.* 1997;28:2180–2184. [Crossref](#). [PubMed](#).
3. Bamford JD, Dennis M. The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire community stroke project. *J Neurol Neurosurg Psychiatry.* 1990;53:824–829 [Crossref](#). [PubMed](#).
4. Stroke Unit Trialists Collaboration. Organised inpatient (stroke unit) care for stroke. *Cochrane Database Syst Rev.* 2007;CD000197. [PubMed](#).
5. Govan L, Langhorne P, Weir CJ; Stroke Unit Trialists Collaboration. Does the prevention of complications explain the survival benefit of organized inpatient (stroke unit) care?: further analysis of a systematic review. *Stroke.* 2007;38:2536–2540. [Crossref](#). [PubMed](#).
6. Davenport RD, MS. Complications after acute stroke. *Stroke.* 1996;27:415–420. [Crossref](#). [PubMed](#).
7. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. *Stroke.* 1998;29:447–453. [Crossref](#). [PubMed](#).
8. Langhorne P, Stott DJ, Robertson L, MacDonald J, Jones L, McAlpine C, et al. Medical complications after stroke: a multicenter study. *Stroke.* 2000;31:1223–1229. [Crossref](#). [PubMed](#).
9. Hong KS, Kang DW, Koo JS, Yu KH, Han MK, Cho YJ, et al. Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke. *Eur J Neurol.* 2008;15:1324–1331. [Crossref](#). [PubMed](#).
10. Indredavik B, Rohweder G, Naalsund E, Lydersen S. Medical complications in a comprehensive stroke unit and an early supported discharge service. *Stroke.* 2008;39:414–420. [Crossref](#). [PubMed](#).
11. Indredavik B, Fjaertoft H, Ekeberg G, Løge AD, Mørch B. Benefit of an extended stroke unit service with early supported discharge: a randomized, controlled trial. *Stroke.* 2000;31:2989–2994. [Crossref](#). [PubMed](#).
12. Fjærtøft H, Rohweder G, Indredavik B. Stroke unit care combined with early supported discharge improves 5-year outcome: a randomized controlled trial. *Stroke.* 2011;42:1707–1711. [Crossref](#). [PubMed](#).
13. Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim LL, Holme I. Benefit of a stroke unit: a randomized controlled trial. *Stroke.* 1991;22:1026–1031. [Crossref](#). [PubMed](#).
14. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Håheim LL. Treatment in a combined acute and rehabilitation stroke unit: which aspects are most important? *Stroke.* 1999;30:917–923. [Crossref](#). [PubMed](#).
15. Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. *Scott Med J.* 1957;2:200–215. [Crossref](#). [PubMed](#).
16. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J; Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. *Stroke.* 2007;38:1911–1915. [Crossref](#). [PubMed](#).
17. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. *Stroke.* 2007;38:3055–3062. [Crossref](#). [PubMed](#).
18. Counsell C, Dennis M, McDowall M, Warlow C. Predicting outcome after acute and subacute stroke: development and validation of new prognostic models. *Stroke.* 2002;33:1041–1047. [Crossref](#). [PubMed](#).

19. Gray LJ, Bath PM, Collier T; Optimising the Analysis of Stroke Trials C. Should stroke trials adjust functional outcome for baseline prognostic factors? *Stroke*. 2009;40:888–894. [Crossref](#). [PubMed](#).
20. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al.; Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. *Lancet*. 2007;370:1432–1442. [Crossref](#). [PubMed](#).
21. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. *Neurology*. 2004;62:569–573. [Crossref](#). [PubMed](#).
22. Mohan KM, Crichton SL, Grieve AP, Rudd AG, Wolfe CD, Heuschmann PU. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. *J Neurol Neurosurg Psychiatry*. 2009;80:1012–1018. [Crossref](#). [PubMed](#).
23. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al.; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med*. 2014;370:2467–2477. [Crossref](#). [PubMed](#).
24. Katzan IL, Cebul RD, Husak SH, Dawson NV, Baker DW. The effect of pneumonia on mortality among patients hospitalized for acute stroke. *Neurology*. 2003;60:620–625. [Crossref](#). [PubMed](#).
25. Sellars C, Bowie L, Bagg J, Sweeney MP, Miller H, Tilston J, et al. Risk factors for chest infection in acute stroke: a prospective cohort study. *Stroke*. 2007;38:2284–2291. [Crossref](#). [PubMed](#).
26. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. *Stroke*. 2005;36:2756–2763. [Crossref](#). [PubMed](#).
27. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. *Stroke*. 2007;38(2 suppl):770–773. [Crossref](#). [PubMed](#).
28. Hinchey JA, Shephard T, Furie K, Smith D, Wang D, Tonn S; Stroke Practice Improvement Network Investigators. Formal dysphagia screening protocols prevent pneumonia. *Stroke*. 2005;36:1972–1976. [Crossref](#). [PubMed](#).
29. Van de Beek D, Wijdicks EF, Vermeij FH, de Haan RJ, Prins JM, Spanjaard L, et al. Preventive antibiotics for infections in acute stroke: a systematic review and meta-analysis. *Arch Neurol*. 2009;66:1076–1081. [Crossref](#). [PubMed](#).
30. Diserens K, Moreira T, Hirt L, Faouzi M, Grujic J, Bieler G, et al. Early mobilization out of bed after ischaemic stroke reduces severe complications but not cerebral blood flow: a randomized controlled pilot trial. *Clin Rehabil*. 2012;26:451–459. [Crossref](#). [PubMed](#).
31. Askim T, Bernhardt J, Salvesen O, Indredavik B. Physical activity early after stroke and its association to functional outcome 3 months later. *J Stroke Cerebrovasc Dis*. 2014;23:e305–e312. [Crossref](#). [PubMed](#).
32. Lynch E, Hillier S, Cadilhac D. When should physical rehabilitation commence after stroke: a systematic review. *Int J Stroke*. 2014;9:468–478. [Crossref](#). [PubMed](#).
33. Cassidy MR, Rosenkranz P, McCabe K, Rosen JE, McAneny D. I COUGH: reducing postoperative pulmonary complications with a multidisciplinary patient care program. *JAMA Surg*. 2013;148:740–745. [Crossref](#). [PubMed](#).
34. Stott DJ, Falconer A, Miller H, Tilston JC, Langhorne P. Urinary tract infection after stroke. *QJM*. 2009;102:243–249. [Crossref](#). [PubMed](#).
35. Kwan J, Hand P. Infection after acute stroke is associated with poor short-term outcome. *Acta Neurol Scand*. 2007;115:331–338. [Crossref](#). [PubMed](#).
36. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, et al. Interventions for preventing falls in older people living in the community. *Cochrane Database Syst Rev*. 2012;9:CD007146.

37. Weerdesteyn V, de Niet M, van Duijnhoven HJ, Geurts AC. Falls in individuals with stroke. *J Rehabil Res Dev*. 2008;*45*:1195–1213. [Crossref](#). [PubMed](#).
38. Ersoz M, Ulusoy H, Oktar MA, Akyuz M. Urinary tract infection and bacteriuria in stroke patients: frequencies, pathogen microorganisms, and risk factors. *Am J Phys Med Rehabil*. 2007;*86*:734–741. [Crossref](#). [PubMed](#).
39. Eriksson M, Norrving B, Terént A, Stegmayr B. Functional outcome 3 months after stroke predicts long-term survival. *Cerebrovasc Dis*. 2008;*25*:423–429. [Crossref](#). [PubMed](#).
40. Miake-Lye IM, Hempel S, Ganz DA, Shekelle PG. Inpatient fall prevention programs as a patient safety strategy: a systematic review. *Ann Intern Med*. 2013;*158*:390–396. [Crossref](#). [PubMed](#).
41. Langhorne P, de Villiers L, Pandian JD. Applicability of stroke unit care to low-income and middle-income countries. *Lancet Neurol*. 2012;*11*:341–348. [Crossref](#). [PubMed](#).